Reza Allamehzadeh, MD
Internal Medicine · Mission Viejo, CANPI 1467606053
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,163 of the $1,773 with a category attached, or 65.6%. Janssen Research & Development, LLC accounts for 73.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $1,302 and has fallen 89.8% since, to $133 in 2025.
Across 26 payments — averaging $68.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- AstraZeneca$223
- Boston Scientific$84
- Bayer$71
- Calliditas Therapeutics US Inc.$47
- Amgen$28
- plus $17 from 1 others
Across 16 payments — averaging $4762.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$58K
- AstraZeneca$12K
- Incyte Corporation$6K
What the payments were for
- Travel & lodging$1,16366%
- Food & beverage$58233%
- Education$272%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 8 | $1,302 |
| AstraZeneca | 6 | $223 |
| Boston Scientific | 3 | $84 |
| Bayer | 4 | $71 |
| Calliditas Therapeutics US Inc. | 3 | $47 |
| Amgen | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,773 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $171,095 |
| JardianceEmpagliflozin | 138 | $166,992 |
| ProliaDenosumab | 81 | $129,976 |
| FarxigaDapagliflozin Propanediol | 149 | $118,754 |
| JanuviaSitagliptin Phosphate | 142 | $118,505 |
| LinzessLinaclotide | 114 | $109,570 |
| EliquisApixaban | 92 | $104,687 |
| MyrbetriqMirabegron | 108 | $99,396 |
| VascepaIcosapent Ethyl | 151 | $90,068 |
| TrulicityDulaglutide | 30 | $59,915 |
| MounjaroTirzepatide | 38 | $41,598 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $34,620 |
| TradjentaLinagliptin | 50 | $34,171 |
| GemtesaVibegron | 37 | $33,794 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $33,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Breztri Aerosphere, Symbicort | $223 | $147,701190 claims |
| AmgenProlia | $28 | $129,97681 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17 | $33,79437 claims |
| BayerKerendia | $71 | $12,95712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Mission Viejo
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.